// App-Quantinova.ai

: Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.

Researchers

Presenter

  • Ronan Le Moigne

Principal Investigators

  • Han-Jie Zhou

  • Jon K. Obst

  • C. Adriana Banuelos

  • Kunzhong Jian

  • David Williams

  • Peter Virsik

  • Raymond J Andersen

  • Marianne Sadar

  • Frank Perabo

  • Kim N. Chi

Medical Centers

  • ESSA Pharmaceuticals, Houston, TX

  • Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada

  • Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Androgen Tear

  • EPI 506

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • NCT02606123

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved